Screening for pancreatic cancer: Why, how, and who?

Annals of Surgery

Volumn 257, Issue 1, 2013, Pages 17-26

  Poruk, Katherine E ^a   Firpo, Matthew A ^a   Adler, Douglas G ^a   Mulvihill, Sean J ^a  

^a UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

Author keywords

High risk groups; pancreatic adenocarcinoma; screening

Indexed keywords

BIOLOGICAL MARKER; BRCA1 PROTEIN; BRCA2 PROTEIN; CA 19-9 ANTIGEN; CARCINOEMBRYONIC ANTIGEN RELATED CELL ADHESION MOLECULE 1; CYCLIN DEPENDENT KINASE INHIBITOR 2A; HEAT SHOCK PROTEIN 27; PROSTATE SPECIFIC ANTIGEN;

AGE DISTRIBUTION; CANCER DIAGNOSIS; CANCER MORTALITY; CANCER SCREENING; CANCER SURVIVAL; CHRONIC PANCREATITIS; COLONOSCOPY; COLORECTAL CANCER; DIABETES MELLITUS; DISTANT METASTASIS; EARLY DIAGNOSIS; ENDOSCOPIC ECHOGRAPHY; ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY; GENE MUTATION; GENETIC RISK; HIGH RISK POPULATION; HUMAN; INTRADUCTAL PAPILLARY MUCINOUS TUMOR; IONIZING RADIATION; NUCLEAR MAGNETIC RESONANCE IMAGING; OBESITY; OCCULT BLOOD TEST; OVERALL SURVIVAL; PANCREAS ADENOMA; PANCREAS CANCER; PEUTZ JEGHERS SYNDROME; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; REVIEW; RISK FACTOR; SENSITIVITY AND SPECIFICITY; SIGMOIDOSCOPY; SMOKING; SURVIVAL RATE; TUMOR LOCALIZATION;

ADENOCARCINOMA; EARLY DETECTION OF CANCER; ENDOSONOGRAPHY; HUMANS; MAGNETIC RESONANCE IMAGING; PANCREATIC NEOPLASMS; PRECANCEROUS CONDITIONS; RISK FACTORS; SENSITIVITY AND SPECIFICITY; TOMOGRAPHY, X-RAY COMPUTED; TUMOR MARKERS, BIOLOGICAL; UNITED STATES;

EID: 84871607730     PISSN: 00034932     EISSN: 15281140     Source Type: Journal    
DOI: 10.1097/SLA.0b013e31825ffbfb     Document Type: Review

References (116)

1. Siegel R, Ward E, Brawley O, et al. Cancer statistics, 2011: the impact of eliminating socioeconomic and racial disparities on premature cancer deaths. CA Cancer JClin. 2011;61:212-236.
2. Compton CC, Mulvihill SJ. Prognostic factors in pancreatic carcinoma. Surg Oncol Clin N Am. 1997;6:533-554. (Pubitemid 27318303)
3. Edwards BK, Ward E, Kohler BA, et al. Annual report to the nation on the status ofcancer, 1975-2006, featuring colorectal cancer trends and impact of interventions (risk factors, screening, and treatment) to reduce future rates. Cancer. 2010;116:544-573.
4. Howlader N, Noone AM, Krapcho M, et al. SEER Cancer Statistics Review, 1975-2008. Bethesda, MD: National Cancer Institute; 2011. Available at: http://seer.cancer.gov/csr/1975-2008/. Accessed February 1, 2011.
5. Crile G, Jr. The advantages ofbypass operations over radical pancreatoduo-denectomy in the treatment of pancreatic carcinoma. Surg Gynecol Obstet. 1970;130:1049-1053.
6. Parikh P, Shiloach M, Cohen ME, et al. Pancreatectomy risk calculator: an ACS-NSQIP resource. HPB (Oxford); 12:488-497.
7. Birkmeyer JD, Siewers AE, Finlayson EV, et al. Hospital volume and surgical mortality in the United States. NEngl JMed. 2002;346:1128-1137. (Pubitemid 34984604)
8. Glasgow RE, Jackson HH, Neumayer L, et al. Pancreatic resection in Veterans Affairs and selected university medical centers: results of the patient safety insurgery study. JAm Coll Surg. 2007;204:1252-1260. (Pubitemid 46819096)
9. Nathan H, Cameron JL, Choti MA, et al. The volume-outcomes effect in hepato-pancreato-biliary surgery: hospital versus surgeon contributions and specificity of the relationship. JAm Coll Surg. 2009;208:528-538.
10. Winter JM, Cameron JL, Lillemoe KD, et al. Periampullary and pancreatic incidentaloma: a single institution's experience with an increasingly common diagnosis. Ann Surg. 2006;243:673-680; discussion680-683. (Pubitemid 44305587)
11. Burris HA, III, Moore MJ, Andersen J, et al. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with ad-vanced pancreas cancer: a randomized trial. J Clin Oncol. 1997;15:2403-2413. (Pubitemid 27251144)
12. Park JK, Yoon YB, Kim YT, et al. Survival and prognostic factors ofunre-sectable pancreatic cancer. J Clin Gastroenterol. 2008;42:86-91.
13. Abou-Alfa GK, Letourneau R, Harker G, et al. Randomized phase III study of exatecan and gemcitabine compared with gemcitabine alone in untreated advancedpancreatic cancer. J Clin Oncol. 2006;24:4441-4447. (Pubitemid 46630982)
14. Colucci G, Labianca R, Di Costanzo F, et al. Randomized phase III trial of gemcitabine plus cisplatin compared with single-agent gemcitabine as first-line treatment ofpatients with advanced pancreatic cancer: the GIP-1 study. JClin Oncol. 2010;28:1645-1651.
15. Conroy T, Desseigne F, Ychou M, et al. FOLFIRINOX versus gemcitabine formetastatic pancreatic cancer. NEngl JMed. 2011;364:1817-1825.
16. Cunningham D, Chau I, Stocken DD, et al. Phase III randomized compar-ison of gemcitabine versus gemcitabine plus capecitabine in patients with advancedpancreatic cancer. J Clin Oncol. 2009;27:5513-5518.
17. Heinemann V, Quietzsch D, Gieseler F, et al. Randomized phase III trial ofgemcitabine plus cisplatin compared with gemcitabine alone in advanced pancreatic cancer. J Clin Oncol. 2006;24:3946-3952. (Pubitemid 46630743)
18. Herrmann R, Bodoky G, Ruhstaller T, et al. Gemcitabine plus capecitabine compared with gemcitabine alone in advanced pancreatic cancer: a random-ized, multicenter, phase III trial of the Swiss Group for Clinical Cancer Re-search and the Central European Cooperative Oncology Group. J Clin Oncol. 2007;25:2212-2217. (Pubitemid 46954645)
19. Kindler HL, Niedzwiecki D, Hollis D, et al. Gemcitabine plus bevacizumab compared with gemcitabine plus placebo in patients with advanced pancreatic cancer: phase III trial ofthe Cancer and Leukemia Group B (CALGB 80303). J Clin Oncol. 2010;28:3617-3622.
20. Louvet C, Labianca R, Hammel P, et al. Gemcitabine in combination with oxaliplatin comparedwith gemcitabine alone in locally advanced or metastatic pancreatic cancer: results of a GERCOR and GISCAD phase III trial. J Clin Oncol. 2005;23:3509-3516.
21. Moore MJ, Goldstein D, Hamm J, et al. Erlotinibplus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol. 2007;25:1960-1966. (Pubitemid 46972777)
22. Philip PA, Benedetti J, Corless CL, et al. Phase III study comparing gem-citabine plus cetuximab versus gemcitabine in patients with advanced pan-creatic adenocarcinoma: Southwest Oncology Group-directed intergroup trial S0205. J Clin Oncol. 2010;28:3605-3610.
23. Poplin E, Feng Y, Berlin J, et al. Phase III, randomized study of gemc-itabine and oxaliplatin versus gemcitabine (fixed-dose rate infusion) com-pared with gemcitabine (30-minute infusion) in patients with pancreatic car-cinoma E6201: a trial of the Eastern Cooperative Oncology Group. J Clin Oncol. 2009;27:3778-3785.
24. Riess H HA, Niedergethmann I. A randomised, prospective, multicenter, phase III trial of gemcitabine, 5-fluorouracil (5-FU), folinic acid vs gem-citabine alone in patients with advanced pancreatic cancer. J Clin Oncol. 2005;23:1092. Abstract4009.
25. Spano JP, Chodkiewicz C, Maurel J, et al. Efficacy ofgemcitabine plus axi-tinib compared with gemcitabine alone in patients with advanced pancreatic cancer: an open-label randomised phase II study. Lancet. 2008;371:2101-2108.
26. Stathopoulos GP, Syrigos K, Aravantinos G, et al. A multicenter phase III trial comparing irinotecan-gemcitabine (IG) with gemcitabine (G) monotherapy as first-line treatment in patients with locally advanced or metastatic pancreatic cancer. Br JCancer. 2006;95:587-592. (Pubitemid 44325898)
27. Van Cutsem E, Vervenne WL, Bennouna J, et al. Phase III trial ofbevacizumab in combination with gemcitabine and erlotinib in patients with metastatic pancreatic cancer. J Clin Oncol. 2009;27:2231-2237.
28. Yachida S, Jones S, Bozic I, et al. Distant metastasis occurs late during the genetic evolutionofpancreatic cancer. Nature. 2010;467:1114-1117.
29. Esserman L, Shieh Y, Thompson I. Rethinking screening for breast cancer andprostate cancer. JAMA. 2009;302:1685-1692.
30. O'Shaughnessy M, Konety B, Warlick C Prostate cancer screening: issues and controversies. Minn Med. 2010;93:39-44.
31. Hardcastle JD, Chamberlain JO, Robinson MH, et al. Randomised con-trolled trial of faecal-occult-blood screening for colorectal cancer. Lancet. 1996;348:1472-1477. (Pubitemid 26400242)
32. Kronborg O, Fenger C, Olsen J, et al. Randomised study of screening for colorectalcancerwithfaecal-occult-bloodtest. Lancet. 1996;348:1467-1471.
33. Mandel JS, Bond JH, Church TR, et al. Reducing mortality from colorectal cancer by screening for fecal occult blood. Minnesota Colon Cancer Control Study. NEngl JMed. 1993;328:1365-1371. (Pubitemid 23131388)
34. Walsh JM, Terdiman JP. Colorectal cancer screening: scientific review. JAMA 2003; 289:1288-1296. (Pubitemid 37432910)
35. Smith RA, Cokkinides V, Brooks D, et al. Cancer screening in the United States, 2011: a review ofcurrent American Cancer Society guidelines and issues in cancer screening. CA Cancer JClin. 2011;61:8-30.
36. Berry DA, Cronin KA, Plevritis SK, et al. Effect of screening and adjuvant therapy on mortality from breast cancer. N Engl J Med. 2005;353:1784-1792. (Pubitemid 41549890)
37. Shen Y, Yang Y, Inoue LY, et al. Role of detection method in predicting breast cancer survival: analysis ofrandomized screening trials. JNatl Cancer Inst. 2005;97:1195-1203. (Pubitemid 41258225)
38. Gotzsche PC, Nielsen M. Screening for breast cancer with mammography. Cochrane Database Syst Rev. 2009:CD001877.
39. Hankey BF, Feuer EJ, Clegg LX, et al. Cancersurveillanceseries: interpreting trends in prostate cancer, part I: evidence of the effects ofscreening in recent prostate cancer incidence, mortality and survival rates. J Natl Cancer Inst. 1999;91:1017-1024. (Pubitemid 29293040)
40. Carroll PR, Whitson JM, Cooperberg MR. Serum prostate-specific antigen for the early detection ofprostate cancer: always, never, or only sometimes? J Clin Oncol. 2011;29:345-347.
41. Loeb S, Vonesh EF, Metter EJ, et al. What is the truenumberneeded to screen and treat to save a life with prostate-specific antigen testing? J Clin Oncol. 2011;29:464-467.
42. Croswell JM, Ransohoff DF, Kramer BS. Principles of cancer screening: lessons from history and study design issues. Semin Oncol. 2010;37:202-215.
43. Hingorani SR, Petricoin EF, Maitra A, et al. Preinvasive and invasive duc-tal pancreatic cancer and its early detection in the mouse. Cancer Cell. 2003;4:437-450. (Pubitemid 38050041)
44. Hingorani SR, Wang L, Multani AS, et al. Trp53R172H and Kras G12D co-operate to promote chromosomal instability and widely metastatic pancreatic ductal adenocarcinoma in mice. Cancer Cell. 2005;7:469-483. (Pubitemid 40719130)
45. Fukuda A, Wang SC, Morris SC JP III, et al. Stat3 and MMP7 contribute to pancreatic ductal adenocarcinoma initiation and progression. Cancer Cell. 2011;19:441-455.
46. La Conti JJ, Shivapurkar N, Preet A, et al. Tissueandserummicro RNAsinthe Kras(G12D) transgenic animal model and in patients with pancreatic cancer. PLo SOne. 2011;6:e20687.
47. Li D, Morris JS, Liu J, et al. Body mass index and risk, age of onset, and survival in patients with pancreatic cancer. JAMA. 2009;301:2553-2562.
48. Vrieling A, Bueno-de-Mesquita HB, Boshuizen HC, et al. Cigarettesmoking, environmental tobacco smoke exposure and pancreatic cancer risk in the European Prospective Investigation into Cancer and Nutrition. Int J Cancer. 2010;126:2394-2403.
49. Boffetta P, Hecht S, Gray N, et al. Smokeless tobacco and cancer. Lancet Oncol. 2008;9:667-675. (Pubitemid 351878052)
50. Ansary-Moghaddam A, Huxley R, Barzi F, et al. The effect ofmodifiable risk factors on pancreatic cancer mortality in populations of the Asia-Pacific region. Cancer Epidemiol Biomarkers Prev. 2006;15:2435-2440. (Pubitemid 46048301)
51. Chari ST, Leibson CL, Rabe KG, et al. Probability ofpancreatic cancer fol-lowingdiabetes: apopulation-basedstudy. Gastroenterology. 2005;129:504-511. (Pubitemid 41096638)
52. Bansal P, Sonnenberg A. Pancreatitis is a risk factor for pancreatic cancer. Gastroenterology. 1995;109:247-251.
53. Lowenfels AB, Maisonneuve P, Cavallini G, et al. Pancreatitis and the risk of pancreatic cancer. International Pancreatitis Study Group. N Engl J Med. 1993;328:1433-1437. (Pubitemid 23143844)
54. Malka D, Hammel P, Maire F, et al. Risk of pancreatic adenocarcinoma in chronic pancreatitis. Gut. 2002;51:849-852. (Pubitemid 35408607)
55. Permuth-Wey J, Egan KM. Family history is a significant risk factor for pancreatic cancer: results from a systematic review and meta-analysis. Fam Cancer. 2009;8:109-117.
56. Shirts BH, Burt RW, Mulvihill SJ, et al. A population-based description of familial clustering of pancreatic cancer. Clin Gastroenterol Hepatol. 2010;8:812-816.
57. Shi C, Hruban RH, Klein AP. Familial pancreatic cancer. Arch Pathol Lab Med. 2009;133:365-374.
58. Al-Sukhni W, Rothenmund H, Borgida AE, etal.Germline BRCA1 mutations predis posetopan creatic adenocarcinoma.Hum Genet. 2008;124:271-278.
59. Lynch HT, Deters CA, Snyder CL, et al. BRCA1 and pancreatic cancer: pedigree findings and their causal relationships. Cancer Genet Cytogenet. 2005;158:119-125. (Pubitemid 40417693)
60. Kastrinos F, Mukherjee B, Tayob N, et al. Risk of pancreatic cancer in families with Lynchsyndrome. JAMA. 2009;302:1790-1795.
61. Goonetilleke KS, Siriwardena AK. System atic review of carbohydrate antigen (CA 19-9) as a biochemical marker in the diagnosis of pancreatic cancer. Eur J Surg Oncol. 2007;33:266-270. (Pubitemid 46488663)
62. Locker GY, Hamilton S, Harris J, et al. ASCO 2006 update ofrecommenda-tions for the use of tumor markers in gastrointestinal cancer. J Clin Oncol. 2006;24:5313-5327. (Pubitemid 46631379)
63. Tempero MA, Uchida E, Takasaki H, et al. Relationship of carbohydrate anti-gen19-9and Lewisantigensinpancreaticcancer. Cancer Res. 1987;47:5501-5503.
64. Barton JG, Bois JP, Sarr MG, et al. Predictive and prognostic value of CA 19-9 inresectedpancreatic adenocarcinoma. JGastrointest Surg. 2009;13:2050-2058.
65. Reni M, Cereda S, Balzano G, et al. Carbohydrate antigen 19-9 change during chemotherapy for advanced pancreatic adenocarcinoma. Cancer. 2009;115:2630-2639.
66. Gold DV, Modrak DE, Ying Z, et al. New MUC1 serum immunoassay dif-ferentiates pancreatic cancer from pancreatitis. J Clin Oncol. 2006;24:252-258. (Pubitemid 46622054)
67. Grote T, Logsdon CD. Progress on molecular markers of pancreatic cancer. Curr Opin Gastroenterol. 2007;23:508-514. (Pubitemid 47356736)
68. Ibis M, Koklu S, Yilmaz FM, et al. Serum adenosine deaminase levels in pancreatic diseases. Pancreatology. 2007;7:526-530. (Pubitemid 47587632)
69. Koopmann J, Fedarko NS, Jain A, et al. Evaluation of osteopontin as biomarker for pancreatic adenocarcinoma. Cancer Epidemiol Biomarkers Prev. 2004;13:487-491. (Pubitemid 38737477)
70. Koopmann J, Rosenzweig CN, Zhang Z, et al. Serum markers in patients with resectable pancreatic adenocarcinoma: macrophage inhibitory cytokine 1 versus CA19-9. Clin Cancer Res. 2006;12:442-446. (Pubitemid 43166133)
71. Kuhlmann KF, van Till JW, Boermeester MA, et al. Evaluation ofmatrix met-alloproteinase 7 in plasma and pancreatic juice as a biomarker for pancreatic cancer. Cancer Epidemiol Biomarkers Prev. 2007;16:886-891. (Pubitemid 46910086)
72. Melle C, Ernst G, Escher N, et al. Protein profiling ofmicrodissected pancreas carcinoma and identification of HSP27 as a potential serum marker. Clin Chem. 2007;53:629-635. (Pubitemid 46580232)
73. Rosty C, Christa L, Kuzdzal S, et al. Identification of hepatocarcinoma-intestine-pancreas/pancreatitis-associated protein I as a biomarker for pan-creatic ductal adenocarcinoma by protein biochip technology Cancer Res. 2002;62:1868-1875. (Pubitemid 34408515)
74. Simeone DM, Ji B, Banerjee M, et al. CEACAM1, a novel serum biomarker for pancreatic cancer. Pancreas. 2007;34:436-443. (Pubitemid 46725785)
75. Firpo MA, Gay DZ, Granger SR, et al. Improved diagnosis of pancreatic adenocarcinoma using haptoglobin and serum amyloid A in a panel screen. World J Surg. 2009;33:716-722.
76. Zhou W, Sokoll LJ, Bruzek DJ, et al. Identifying markers for pancreatic cancer by gene expression analysis. Cancer Epidemiol Biomarkers Prev. 1998;7:109-112. (Pubitemid 28109841)
77. Jones S, Zhang X, Parsons DW, et al. Core signaling pathways in hu-man pancreatic cancers revealed by global genomic analyses. Science. 2008;321:1801-1806.
78. Harsha HC, Kandasamy K, Ranganathan P, et al. A compendium ofpotential biomarkers of pancreatic cancer. PLo SMed. 2009;6:e1000046.
79. Friel AM, Corcoran C, Crown J, et al. Relevance of circulating tumor cells, extracellular nucleic acids, and exosomes in breast cancer. Breast Cancer Res Treat. 2010;123:613-625.
80. Rabinowits G, Gercel-Taylor C, Day JM, et al. Exosomal micro RNA: a diag-nostic marker for lung cancer. Clin Lung Cancer. 2009;10:42-46.
81. Skog J, Wurdinger T, van Rijn S, et al. Glioblastoma microvesicles trans-port RNA and proteins that promote tumour growth and provide diagnostic biomarkers. Nat Cell Biol. 2008;10:1470-1476.
82. Taylor DD, Gercel-Taylor C. Micro RNA signatures of tumor-derived ex-osomes as diagnostic biomarkers of ovarian cancer. Gynecol Oncol. 2008;110:13-21. (Pubitemid 351853251)
83. Bryzgunova OE, Morozkin ES, Yarmoschuk SV, et al. Methylation-specific sequencing of GSTP1 gene promoter in circulating/extracellular DNA from blood and urine ofhealthy donors and prostate cancer patients. Ann N YAcad Sci. 2008;1137:222-225.
84. Chan KC, Lai PB, Mok TS, et al. Quantitative analysis of circulating methylated DNA as a biomarker for hepatocellular carcinoma. Clin Chem. 2008;54:1528-1536.
85. Ellinger J, Albers P, Perabo FG, et al. Cp G island hypermethylation of cell-free circulating serum DNA in patients with testicular cancer. J Urol. 2009;182:324-329.
86. Radpour R, Barekati Z, Kohler C, et al. Hypermethylation of tumor suppressor genes involved in critical regulatory pathways for developing a blood-based test in breast cancer. PLo S One. 2011;6:e16080.
87. Deer EL, Gonzalez-Hernandez J, Coursen JD, et al. Phenotype and genotype of pancreatic cancer cell lines. Pancreas. 2010;39:425-435.
88. Kurihara T, Itoi T, Sofuni A, et al. Detection ofcirculating tumor cells in patientswithpancreaticcancer: apreliminaryresult. JHepatobiliary Pancreat Surg. 2008;15:189-195. (Pubitemid 351516978)
89. Stott SL, Hsu CH, Tsukrov DI, et al. Isolation of circulating tumor cells using a microvortex-generating herringbone-chip. Proc Natl Acad Sci USA. 2010;107:18392-18397.
90. Shi C, Fukushima N, Abe T, et al. Sensitive and quantitative detection of KRAS2 gene mutations in pancreatic duct juice differentiates patients with pancreatic cancer from chronic pancreatitis, potential for early detection. Cancer Biol Ther. 2008;7:353-360. (Pubitemid 351847047)
91. Suehara N, Mizumoto K, Tanaka M, et al. Telomerase activity in pancreatic juice differentiates ductal carcinoma from adenoma and pancreatitis. Clin Cancer Res. 1997;3:2479-2483. (Pubitemid 28133171)
92. Uehara H, Nakaizumi A, Tatsuta M, et al. Diagnosis of pancreatic cancer by detecting telomerase activity in pancreatic juice: comparison with K-ras mutations. Am J Gastroenterol. 1999;94:2513-2518. (Pubitemid 29420682)
93. Cheng CL, Sherman S, Watkins JL, et al. Risk factors for post-ERCP pancre-atitis: a prospective multicenter study. Am J Gastroenterol. 2006;101:139-147. (Pubitemid 43381722)
94. Williams EJ, Taylor S, Fairclough P, et al. Risk factors for complication following ERCP; results of a large-scale, prospective multicenter study. En-doscopy. 2007;39:793-801. (Pubitemid 47386828)
95. Volmar KE, Vollmer RT, Routbort MJ, et al. Pancreatic andbileductbrushing cytology in 1000 cases: review offindings and comparison of preparation methods. Cancer. 2006;108:231-238. (Pubitemid 44835770)
96. Long EE, Van Dam J, Weinstein S, et al. Computed tomography endoscopic, laparoscopic, and intra-operative sonography for assessing resectability of pancreatic cancer. Surg Oncol. 2005;14:105-113. (Pubitemid 41207196)
97. De Witt J, Devereaux B, Chriswell M, et al. Comparison ofendoscopic ultra-sonography andmultidetector computed tomography for detecting and staging pancreatic cancer. Ann Intern Med. 2004;141:753-763.
98. Sahani DV, Shah ZK, Catalano OA, et al. Radiology of pancreatic adenocar-cinoma: current status ofimaging. J Gastroenterol Hepatol. 2008;23:23-33. (Pubitemid 350265200)
99. Bluemke DA, Fishman EK. CT and MR evaluation of pancreatic cancer. Surg Oncol Clin N Am. 1998;7:103-124. (Pubitemid 28108795)
100. Beinfeld MT, Wittenberg E, Gazelle GS. Cost-effectiveness ofwhole-body CT screening. Radiology. 2005;234:415-422.
101. Hruban RH, Goggins M, Parsons J, et al. Progression model for pancreatic cancer. Clin Cancer Res. 2000;6:2969-2972. (Pubitemid 30637716)
102. Kozuka S, Sassa R, Taki T, et al. Relation of pancreatic duct hyperplasia to carcinoma. Cancer. 1979;43:1418-1428. (Pubitemid 9180309)
103. Cubilla AL, Fitzgerald PJ. Morphological lesions associated with human primary invasive nonendocrine pancreas cancer. Cancer Res. 1976;36:2690-2698.
104. Andea A, Sarkar F, Adsay VN. Clinicopathological correlates of pancreatic intraepithelial neoplasia: a comparative analysis of 82 cases with and 152 cases withoutpancreatic ductal adenocarcinoma. Mod Pathol. 2003;16:996-1006. (Pubitemid 37280815)
105. Shi C, Klein AP, Goggins M, et al. Increased prevalence of precursor le-sions infamilialpancreatic cancerpatients. Clin Cancer Res. 2009;15:7737-7743.
106. Hruban RH, Maitra A, Goggins M. Update on pancreatic intraepithelial neo-plasia. Int J Clin Exp Pathol. 2008;1:306-316.
107. Tanaka M, Chari S, Adsay V, et al. International consensus guidelines for management ofintraductal papillary mucinous neoplasms and mucinous cys-tic neoplasms of the pancreas. Pancreatology. 2006;6:17-32.
108. Brentnall TA, Bronner MP, Byrd DR, et al. Early diagnosis and treatment of pancreatic dysplasia in patients with a family history of pancreatic cancer. Ann Intern Med. 1999;131:247-255. (Pubitemid 29383653)
109. Canto MI, Goggins M, Hruban RH, et al. Screening for early pancreatic neoplasia in high-risk individuals: a prospective controlled study. Clin Gas-troenterol Hepatol. 2006;4:766-781; quiz 665. (Pubitemid 43825802)
110. Canto MI, Goggins M, Yeo CJ, et al. Screening for pancreatic neoplasia in high-risk individuals: an EUS-based approach. Clin Gastroenterol Hepatol. 2004;2:606-621. (Pubitemid 38834045)
111. Chu D, Kohlmann W, Adler DG. Identification and screening of individuals at increased risk for pancreatic cancer with emphasis on known environ-mental and genetic factors and hereditary syndromes. JOP. 2010;11:203-212.
112. Klapman J, Malafa MP. Early detection of pancreatic cancer: why, who, and how to screen. Cancer Control. 2008;15:280-287.
113. Langer P, Kann PH, Fendrich V, et al. Five years ofprospective screening ofhigh-risk individuals from families with familial pancreatic cancer. Gut. 2009;58:1410-1418.
114. Ludwig E, Olson SH, Bayuga S, et al. Feasibility and yield of screening in relatives from familial pancreatic cancer families. Am J Gastroenterol. 2011;106:946-954.
115. Poley JW, Kluijt I, Gouma DJ, et al. The yield of first-time endoscopic ultra-sonography in screening individuals at a high risk of developing pancreatic cancer. Am J Gastroenterol. 2009;104:2175-2181.
116. Verna EC, Hwang C, Stevens PD, et al. Pancreatic cancer screening in a prospective cohort ofhigh-risk patients: a comprehensive strategy ofimaging andgenetics. Clin Cancer Res. 2010;16:5028-5037.